

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

**VOLUNTARY ANNOUNCEMENT
ESTIMATED INTERIM RESULTS AND BUSINESS UPDATES
FOR THE SIX MONTHS ENDED 30 JUNE 2024**

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, for the purpose of updating the shareholders of the Company on the business of the Group.

The board of directors of the Company (the “**Board**”) wishes to inform holders of the shares and securities of the Company and potential investors that, benefiting from the further increase in market share driven by the commercialization of the leading products from the Group, the incremental revenue generated from new products’ contribution and the rapid growth from overseas sales as a result of the continuous expansion of our global business, the Group achieved steady growth in revenue for the six months ended 30 June 2024 (the “**Period**”). According to preliminary estimation by the management of the Company, the revenue of the Group for the Period increased by approximately 17% over the corresponding period of the previous year (excluding the effect of exchange rates on such revenue growth rate and the revenue growth rates shown in this announcement), and achieved a significant year-on-year decrease in net loss. The major growth in each of the major business segments during the Period is set out below:

- i. The subsidiaries that are separately listed all achieved strong year-on-year revenue growth*, with MicroPort NeuroTech Limited (neurovascular devices business) (“**MicroPort NeuroTech**”) grew year-on-year by approximately 34% to 37%, revenue from Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (endovascular and peripheral vascular devices business) (“**EV MedTech**”) grew year-on-year by 25% to 30%, revenue from MicroPort CardioFlow Medtech Corporation (heart valve business) (“**CardioFlow Medtech**”) grew year-on-year by approximately 22% to 28% and revenue from Shanghai MicroPort MedBot (Group) Co., Ltd. (surgical robot business) (“**MicroPort MedBot**”) also achieved a year-on-year growth by approximately 103% to 108%;
- ii. Other major businesses within the Group have further consolidated their competitive advantages and achieved steady revenue growth, among which, the revenue from the cardiovascular devices business, the orthopedics devices business and the cardiac rhythm management business increased by approximately 14%, 10% and 6% year-on-year, respectively;
- iii. During the Period, leveraging the Group’s going abroad platform’s extensive and in-depth global distribution layout, business segments effectively and constantly exported competitive products with excellent clinical performance, resulting in a steady increase in revenue of the Group’s going abroad business by more than 40% over the corresponding period of the last year.

* Revenue from the subsidiaries has not excluded intragroup transactions.

The Company expects that the subsequent launch of products with broad market potential and further leveraging of going abroad platforms as well as other distribution channels will bring more growth momentum to the Group and help the Group continue to improve its revenue performance.

At the same time, since 2024, the Group also adhered to its focus on improving profitability. By concentrating on core business and optimizing resource allocation, the Group has been strictly controlling and reducing R&D and administrative expenses, while allocating sales expenses to be in line with the rapid revenue growth, and it is expected to achieve a significant reduction in losses during the Period. The Group will also continue to enhance the cost control and strive to gradually achieve breakeven.

As at the date of this announcement, the Company is still in the process of preparing and completing the unaudited interim results of the Group for the six months ended 30 June 2024 (the “**2024 Interim Results**”). The information contained in this announcement is based on a preliminary assessment of the business operation information currently available to the Board and is not based on any financial information or information which have been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the Company’s shares and securities and potential investors are advised to read the Company’s announcement for the 2024 Interim Results carefully, which is expected to be published by the end of August 2024. Holders of the Company’s shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 8 July 2024

As at the date of this announcement, the executive director of the Company is Dr. Zhaohua Chang; the non-executive directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida and Ms. Weiqin Sun; and the independent non-executive directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

** For identification purpose only*